What question did this study set out to answer?

This research aims to evaluate the prognostic impact of different IKZF1 deletion subtypes in patients with BCP-ALL undergoing allo-HCT, especially those that are Ph-negative and TP53-wild type.

December 8, 2025Blood

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

View Full Paper

Ask AI

Bookmark

Authors

SLSeung‐Hwan Lee DKDaehun Kwag SPSung Soo Park

Discussion

Member takes

Overview

Retrospective analysis shows IKZF1 deletions impact survival in Ph-negative BCP-ALL, suggesting targeted therapies needed.

Key Points

This research aims to evaluate the prognostic impact of different IKZF1 deletion subtypes in patients with BCP-ALL undergoing allo-HCT, especially those that are Ph-negative and TP53-wild type.
Retrospective analysis of 389 adult BCP-ALL patients
Identified IKZF1 deletions and alterations in genes via multiplex ligation-dependent probe amplification
Performed targeted next-generation sequencing of 73 genes
Conducted MRD monitoring using NGS-based IGH/IGK rearrangement and multiparameter flow cytometry
Assessed survival outcomes using Kaplan-Meier and competing risk models.
Observed 210 patients with IKZF1 deletions, with 52 being Ph-negative
In Ph-negative BCP-ALL, IKZF1 deletion correlated with worse 3-year disease-free survival (36.8%)
Biallelic-null IKZF1 deletions led to the lowest 3-year overall survival (33.3%) in TP53-wild type patients

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d888 https://doi.org/10.1182/blood-2025-5149

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

View Full Paper

Ask AI

Bookmark

Authors

SLSeung‐Hwan Lee DKDaehun Kwag SPSung Soo Park

Discussion

Member takes

Overview

Retrospective analysis shows IKZF1 deletions impact survival in Ph-negative BCP-ALL, suggesting targeted therapies needed.

Key Points

This research aims to evaluate the prognostic impact of different IKZF1 deletion subtypes in patients with BCP-ALL undergoing allo-HCT, especially those that are Ph-negative and TP53-wild type.
Retrospective analysis of 389 adult BCP-ALL patients
Identified IKZF1 deletions and alterations in genes via multiplex ligation-dependent probe amplification
Performed targeted next-generation sequencing of 73 genes
Conducted MRD monitoring using NGS-based IGH/IGK rearrangement and multiparameter flow cytometry
Assessed survival outcomes using Kaplan-Meier and competing risk models.
Observed 210 patients with IKZF1 deletions, with 52 being Ph-negative
In Ph-negative BCP-ALL, IKZF1 deletion correlated with worse 3-year disease-free survival (36.8%)
Biallelic-null IKZF1 deletions led to the lowest 3-year overall survival (33.3%) in TP53-wild type patients

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d888 https://doi.org/10.1182/blood-2025-5149

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark